Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Faslodex rejected for use on NHS

  • Comment

The breast cancer drug Faslodex does not offer value for money to the NHS and is no better than existing treatments, according to NICE.

The agency’s final draft guidance ruled that Faslodex, also known as fulvestrant, should not be given out on the NHS to postmenopausal women who have oestrogen-receptor-positive advanced breast cancer and who have already received another anti-oestrogen therapy (such as tamoxifen).

AstraZeneca claimed it could extend life when compared with two existing drugs, anastrozole and letrozole, said NICE.

But the agency found the manufacturer’s assertion to be “considerably uncertain” and said evidence showed no statistically significant differences in overall survival. It did find Faslodex could delay cancer growth better than anastrozole, but said there was no evidence it was better at this function than letrozole.

The decision, which is subject to an appeals procedure, does not affect women already on Faslodex. They will be able to continue taking it until otherwise advised by their doctors.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.